Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| basal cell | 11 studies | 33% ± 17% | |
| adipocyte | 9 studies | 36% ± 19% | |
| secretory cell | 7 studies | 33% ± 14% | |
| respiratory goblet cell | 6 studies | 40% ± 8% | |
| club cell | 5 studies | 42% ± 15% | |
| ciliated cell | 4 studies | 32% ± 17% | |
| hepatocyte | 4 studies | 48% ± 11% | |
| duct epithelial cell | 3 studies | 31% ± 14% | |
| epithelial cell | 3 studies | 31% ± 5% | |
| fibroblast | 3 studies | 26% ± 4% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| liver | 100% | 11753.86 | 226 / 226 | 89% | 140.13 | 362 / 406 |
| bladder | 81% | 6284.14 | 17 / 21 | 52% | 93.73 | 260 / 504 |
| esophagus | 73% | 3433.19 | 1062 / 1445 | 54% | 128.05 | 98 / 183 |
| lung | 68% | 1182.33 | 392 / 578 | 54% | 204.95 | 623 / 1155 |
| breast | 92% | 8571.72 | 420 / 459 | 14% | 6.38 | 162 / 1118 |
| ureter | 0% | 0 | 0 / 0 | 100% | 39.32 | 1 / 1 |
| adipose | 98% | 12499.21 | 1184 / 1204 | 0% | 0 | 0 / 0 |
| blood vessel | 94% | 2912.14 | 1256 / 1335 | 0% | 0 | 0 / 0 |
| muscle | 92% | 6456.62 | 741 / 803 | 0% | 0 | 0 / 0 |
| skin | 81% | 1493.95 | 1464 / 1809 | 1% | 0.17 | 5 / 472 |
| thymus | 79% | 2146.88 | 517 / 653 | 2% | 3.87 | 13 / 605 |
| stomach | 69% | 4501.69 | 246 / 359 | 9% | 1.76 | 25 / 286 |
| adrenal gland | 20% | 238.02 | 51 / 258 | 46% | 12.51 | 105 / 230 |
| heart | 61% | 1504.20 | 523 / 861 | 0% | 0 | 0 / 0 |
| intestine | 51% | 1112.18 | 491 / 966 | 8% | 2.82 | 44 / 527 |
| kidney | 29% | 571.21 | 26 / 89 | 25% | 13.55 | 226 / 901 |
| tonsil | 0% | 0 | 0 / 0 | 47% | 52.84 | 21 / 45 |
| uterus | 6% | 66.22 | 11 / 170 | 38% | 62.10 | 175 / 459 |
| pancreas | 6% | 96.09 | 21 / 328 | 38% | 11.67 | 67 / 178 |
| prostate | 28% | 423.97 | 68 / 245 | 1% | 0.16 | 3 / 502 |
| ovary | 17% | 180.50 | 30 / 180 | 1% | 0.12 | 4 / 430 |
| brain | 7% | 85.28 | 192 / 2642 | 2% | 0.35 | 12 / 705 |
| peripheral blood | 2% | 63.27 | 14 / 929 | 0% | 0 | 0 / 0 |
| spleen | 1% | 17.82 | 3 / 241 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| GO_0044597 | Biological process | daunorubicin metabolic process |
| GO_0071799 | Biological process | cellular response to prostaglandin D stimulus |
| GO_0044598 | Biological process | doxorubicin metabolic process |
| GO_0071395 | Biological process | cellular response to jasmonic acid stimulus |
| GO_0030855 | Biological process | epithelial cell differentiation |
| GO_0007586 | Biological process | digestion |
| GO_0042448 | Biological process | progesterone metabolic process |
| GO_0007186 | Biological process | G protein-coupled receptor signaling pathway |
| GO_0006693 | Biological process | prostaglandin metabolic process |
| GO_0051897 | Biological process | positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction |
| GO_0008284 | Biological process | positive regulation of cell population proliferation |
| GO_0008202 | Biological process | steroid metabolic process |
| GO_0005829 | Cellular component | cytosol |
| GO_0047086 | Molecular function | ketosteroid monooxygenase activity |
| GO_0018636 | Molecular function | phenanthrene 9,10-monooxygenase activity |
| GO_0004032 | Molecular function | aldose reductase (NADPH) activity |
| GO_0047044 | Molecular function | androstan-3-alpha,17-beta-diol dehydrogenase activity |
| GO_0016655 | Molecular function | oxidoreductase activity, acting on NAD(P)H, quinone or similar compound as acceptor |
| GO_0047718 | Molecular function | indanol dehydrogenase activity |
| GO_0047023 | Molecular function | androsterone dehydrogenase activity |
| GO_0032052 | Molecular function | bile acid binding |
| GO_0004303 | Molecular function | estradiol 17-beta-dehydrogenase [NAD(P)+] activity |
| GO_0031406 | Molecular function | carboxylic acid binding |
| GO_0047115 | Molecular function | trans-1,2-dihydrobenzene-1,2-diol dehydrogenase activity |
| Gene name | AKR1C2 |
| Protein name | Aldo-keto reductase family 1 member C2 (EC 1.-.-.-) (EC 1.1.1.112) (EC 1.1.1.209) (EC 1.1.1.53) (EC 1.1.1.62) (EC 1.3.1.20) (3-alpha-HSD3) (Chlordecone reductase homolog HAKRD) (Dihydrodiol dehydrogenase 2) (DD-2) (DD2) (Dihydrodiol dehydrogenase/bile acid-binding protein) (DD/BABP) (Type III 3-alpha-hydroxysteroid dehydrogenase) (EC 1.1.1.357) 3 alpha hydroxysteroid dehydrogenase III (EC 1.1.1.213) Aldo-keto reductase family 1 member C2 |
| Synonyms | DDH2 |
| Description | FUNCTION: Cytosolic aldo-keto reductase that catalyzes the NADH and NADPH-dependent reduction of ketosteroids to hydroxysteroids . Most probably acts as a reductase in vivo since the oxidase activity measured in vitro is inhibited by physiological concentrations of NADPH . Displays a broad positional specificity acting on positions 3, 17 and 20 of steroids and regulates the metabolism of hormones like estrogens and androgens . Works in concert with the 5-alpha/5-beta-steroid reductases to convert steroid hormones into the 3-alpha/5-alpha and 3-alpha/5-beta-tetrahydrosteroids. Catalyzes the inactivation of the most potent androgen 5-alpha-dihydrotestosterone (5-alpha-DHT) to 5-alpha-androstane-3-alpha,17-beta-diol (3-alpha-diol) . Also specifically able to produce 17beta-hydroxy-5alpha-androstan-3-one/5alphaDHT . May also reduce conjugated steroids such as 5alpha-dihydrotestosterone sulfate . Displays affinity for bile acids . . |
| Accessions | ENST00000455190.2 [P52895-2] ENST00000380753.9 [P52895-1] ENST00000421196.7 S4R3P0 Q1KXY7 B4DK69 ENST00000604507.5 P52895 |
